Video

Dr. Andreadis on Treatment Approaches in Relapsed MCL

Charalambos (Babis) Andreadis, MD, MSCE, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma (MCL).

Multiple intensive therapies including autologous stem cell transplantation may be used up front for patients with untreated MCL to elicit a favorable response. However, few options exist for patients upon relapse, explains Andreadis.

Currently, BTK inhibition with ibrutinib (Imbruvica) or a similar agent may be used, says Andreadis. Ongoing clinical trials also suggest that proteasome inhibitors like carfilzomib (Kyprolis) and bortezomib (Velcade) may have activity in this space.

Patients with relapsed disease who respond to treatment should be considered for allogeneic transplant. However, the introduction of a novel agent into this space could mitigate the increased toxicity associated with allogeneic transplant, concludes Andreadis.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity